For example, using a Polθ inhibitor in combination with or after a PARP inhibitor in patients with BRCA1 mutant cancers might prevent the emergence of otherwise drug resistant 53BP1/Shieldin defective tumour cell clones. Here, PARP1 is linked to neoplasm.